Antineoplastic treatment with crizotinib during pregnancy: a case report

Kristian H Jensen; Gitte Persson; Lone Storgaard; Birgitte B Nielsen; Berit W Pedersen; Lisa L Maroun; Alwin Huitema; Mette Pøhl

doi:10.1080/0284186X.2018.1497302

Antineoplastic treatment with crizotinib during pregnancy: a case report

Kristian H Jensen
, Gitte Persson
, Lone Storgaard
, Birgitte B Nielsen
, Berit W Pedersen
, Lisa L Maroun
, Alwin Huitema
, Mette Pøhl

Clinical Pharmacy

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.

Original language	English
Pages (from-to)	121-122
Number of pages	2
Journal	Acta Oncologica
Volume	58
Issue number	1
Early online date	11 Aug 2018
DOIs	https://doi.org/10.1080/0284186X.2018.1497302
Publication status	Published - Jan 2019

Keywords

Crizotinib/therapeutic use
Pregnancy
Pregnancy Complications, Neoplastic/drug therapy
Humans
Lung Neoplasms/drug therapy
Antineoplastic Agents/therapeutic use
Fatal Outcome
HELLP Syndrome/etiology
Adult
Female
Adenocarcinoma of Lung/drug therapy

Access to Document

10.1080/0284186X.2018.1497302

jensenFinal published version, 890 KBLicence: Taverne

Cite this

@article{594b438a43cd4140b88a2c6e327b69ef,

title = "Antineoplastic treatment with crizotinib during pregnancy: a case report",

abstract = "The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.",

keywords = "Crizotinib/therapeutic use, Pregnancy, Pregnancy Complications, Neoplastic/drug therapy, Humans, Lung Neoplasms/drug therapy, Antineoplastic Agents/therapeutic use, Fatal Outcome, HELLP Syndrome/etiology, Adult, Female, Adenocarcinoma of Lung/drug therapy",

author = "Jensen, \{Kristian H\} and Gitte Persson and Lone Storgaard and Nielsen, \{Birgitte B\} and Pedersen, \{Berit W\} and Maroun, \{Lisa L\} and Alwin Huitema and Mette P{\o}hl",

year = "2019",

month = jan,

doi = "10.1080/0284186X.2018.1497302",

language = "English",

volume = "58",

pages = "121--122",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "1",

}

TY - JOUR

T1 - Antineoplastic treatment with crizotinib during pregnancy

T2 - a case report

AU - Jensen, Kristian H

AU - Persson, Gitte

AU - Storgaard, Lone

AU - Nielsen, Birgitte B

AU - Pedersen, Berit W

AU - Maroun, Lisa L

AU - Huitema, Alwin

AU - Pøhl, Mette

PY - 2019/1

Y1 - 2019/1

N2 - The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.

AB - The rare concurrence of pregnancy and lung cancer presents a significant clinical challenge. In younger patients, the presence of molecular driver mutations is more frequently observed [1], but treatment experience with newer targeted therapies during pregnancy is extremely limited. Here, we present a patient who was diagnosed with anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC) and received treatment with the ALK inhibitor crizotinib during pregnancy.

KW - Crizotinib/therapeutic use

KW - Pregnancy

KW - Pregnancy Complications, Neoplastic/drug therapy

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Antineoplastic Agents/therapeutic use

KW - Fatal Outcome

KW - HELLP Syndrome/etiology

KW - Adult

KW - Female

KW - Adenocarcinoma of Lung/drug therapy

UR - https://www.scopus.com/pages/publications/85061578145

U2 - 10.1080/0284186X.2018.1497302

DO - 10.1080/0284186X.2018.1497302

M3 - Comment/Letter to the editor

C2 - 30101631

SN - 0284-186X

VL - 58

SP - 121

EP - 122

JO - Acta Oncologica

JF - Acta Oncologica

IS - 1

ER -

Antineoplastic treatment with crizotinib during pregnancy: a case report

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this